NCT07412158 2026-02-17
Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)
Peking University First Hospital
Completed
Clinical Trials
17 trialsNCT01022515 2026-02-06
PHEO
University Hospital, Rouen
Phase NA Completed
NCT02302833 2025-07-31
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT06669481 2024-11-01
Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics
Peking Union Medical College Hospital
Completed
NCT00843037 2024-10-17
SNIPP
University Health Network, Toronto
Phase 2 Completed
NCT04860700 2024-06-12
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Peking Union Medical College Hospital
Phase 2 Completed
NCT03176693 2023-11-20
Preoperative Alpha Blockade for Pheochromocytoma
University of California, Los Angeles
Phase 3 Completed
NCT05942482 2023-09-15
Head and Neck Paragangliomas: A 16-year Experience of a University Hospital in Turkey
Pamukkale University
Completed
NCT05858177 2023-05-15
MPPGL
Peking Union Medical College Hospital
Phase 2 Completed
NCT02186678 2023-04-06
DOTATATE
Assistance Publique Hopitaux De Marseille
Phase NA Completed
NCT00442533 2023-04-03
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Phase 2/3 Completed
NCT01371201 2022-08-04
FIRSTMAPPP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT01347307 2020-06-18
Stereotactic Body Radiotherapy for Spine Tumors
Mercy Research
Phase NA Completed
NCT01635907 2020-04-14
Dovitinib in Neuroendocrine Tumors
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02672020 2019-09-24
COMETETACTIC
Assistance Publique - Hôpitaux de Paris
Phase NA Completed
NCT01413503 2018-09-18
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
Phase 2 Completed